Ido Goldenberg

Ido Goldenberg

Auto-generated profile, based on publicly available information

Ido Goldenberg

Clinical Cardiovascular Research Center University of Rochester, Rochester New York USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2016 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
AEAharon Erez
Aharon Erez
IGIlan Goldenberg
Ilan Goldenberg
ASAvi Sabbag
Avi Sabbag
ENEyal Nof
Eyal Nof
DZDoron Zahger
Doron Zahger
RBRoy Beinart
Roy Beinart
Background: The past decade has brought major advances in therapy of patients presenting with acute coronary syndromes (ACS).Hypothesis: The outcomes of ACS patients with atrial fibrillation (AF) has improved over the years.Methods: We evaluated time‐dependent changes in clinical characteristics, management strategies, and outcomes associated with AF observed during ACS hospitalization in patients enrolled in the biannual ACS Israeli Surveys (ACSIS) between 2000 and 2013. We divided the surveys into early (2000–2006) and late (2008–2013) time periods.Results: The study population comprised 13 297 ACS patients, of whom 755 (5.7%) either presented with or developed AF during the index hospitalization. The incidence of AF observed during ACS hospitalization was lower during the later period (6.2% vs 4.9%; P < 0.01). Kaplan‐Meier survival analysis showed that 1‐year mortality rates were significantly lower among ACS patients with and without AF who were enrolled during the later vs early survey period (log‐rank P < 0.01 for the overall difference). However, AF observed among ACS patients was still associated with increased risk for in‐hospital complications and 30‐day and 1‐year mortality during both the early and late survey periods (P < 0.05 for all comparisons).Conclusions: In 10 years, rates of AF among ACS patients have declined significantly. Yet, despite improved overall 1‐year survival for patients with AF, the development of AF in this population remains an independent predictor of mortality that has not changed appreciably over the years.

1 March 2021 in Heart Rhythm
Verified
Journal Article
Open access
IGIdo Goldenberg
Ido Goldenberg
JEJulia W. Erath
Julia W. Erath
ARAndrea M. Russo
Andrea M. Russo
ABAshley E. Burch
Ashley E. Burch
BABirgit Assmus
Birgit Assmus
VKValentina Kutyifa
Valentina Kutyifa
Data on the arrhythmic burden of women at risk for sudden cardiac death are limited, especially in patients using the wearable cardioverter-defibrillator (WCD). We aimed to characterize WCD compliance, atrial and ventricular arrhythmic burden, and WCD outcomes by sex in patients enrolled in the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II U.S. Registry). In the WEARIT-II Registry, we stratified 2000 patients by sex into women (n = 598) and men (n = 1402). WCD wear time, ventricular and atrial arrhythmic events during WCD use, and implantable cardioverter-defibrillator (ICD) implantation rates at the end of WCD use were evaluated. The mean WCD wear time was similar in women and men (94 days vs 90 days; P = .145), with longer daily use in women (21.4 h/d vs 20.7 h/d; P = .001). Burden of ventricular tachycardia or ventricular fibrillation was higher in women, with 30 events per 100 patient-years compared with 18 events per 100 patient-years in men (P = .017), with similar findings for treated and non-treated ventricular tachycardia/ventricular fibrillation. Recurrent atrial arrhythmias/sustained ventricular tachycardia was also more frequent in women than in men (167 events per 100 patient-years vs 73 events per 100 patient-years; P = .042). However, ICD implantation rate at the end of WCD use was similar in both women and men (41% vs 39%; P = .448). In the WEARIT-II Registry, we have shown a higher burden of ventricular and atrial arrhythmic events in women than in men. ICD implantation rates at the end of WCD use were similar. Our findings warrant monitoring women at risk for sudden cardiac death who have a high burden of atrial and ventricular arrhythmias while using the WCD.

1 December 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
IGIdo Goldenberg
Ido Goldenberg
ABAlon Barsheshet
Alon Barsheshet
ALAvishag Laish-Farkash
Avishag Laish-Farkash
MSMoshe Swissa
Moshe Swissa
JSJorge E. Schliamser
Jorge E. Schliamser
MSMahmoud Suleiman
Mahmoud Suleiman

18 July 2023 in Circulation
Verified
Journal Article
Closed access
AYArwa Younis
Arwa Younis
SASanah Ali
Sanah Ali
EHEileen Hsich
Eileen Hsich
IGIdo Goldenberg
Ido Goldenberg
SMScott McNitt
Scott McNitt
IGIlan Goldenberg
Ilan Goldenberg
BACKGROUND: Black Americans have a higher risk of nonischemic cardiomyopathy (NICM) than White Americans. We aimed to evaluate differences in the risk of tachyarrhythmias among patients with an implantable cardioverter-defibrillator (ICD). METHODS: The study population comprised 3895 ICD recipients in the United States enrolled in primary prevention ICD trials. Outcome measures included ventricular tachyarrhythmia (VTA), atrial tachyarrhythmia (ATA), ICD therapies, VTA burden (using Andersen-Gill recurrent event analysis), death, and the predicted benefit of the ICD. All events were adjudicated blindly. Outcomes were compared between self-reported Black patients versus White patients with cardiomyopathy (ischemic and NICM). RESULTS: Black patients were more likely to be female (35% versus 22%) and younger (57±12 versus 62±12 years) with a higher frequency of comorbidities. In NICM, Black patients had a higher rate of first VTA, fast VTA, ATA, and appropriate and inappropriate ICD therapy (VTA ≥170 bpm, 32% versus 20%; VTA ≥200 bpm, 22% versus 14%; ATA, 25% versus 12%; appropriate therapy, 30% versus 20%; and inappropriate therapy, 25% versus 11%; P <0.001 for all). Multivariable analysis showed that Black patients with NICM experienced a higher risk of all types of arrhythmia or ICD therapy (VTA ≥170 bpm, hazard ratio [HR] 1.71; VTA ≥200 bpm, HR 1.58; ATA, HR 1.87; appropriate therapy, HR 1.62; inappropriate therapy, HR 1.86; P ≤0.01 for all), higher burden of tachyarrhythmias or therapies (VTA, HR 1.84; appropriate therapy, HR 1.84; P <0.001 for both), and a higher risk of death (HR 1.92; P =0.014). In contrast, in ischemic cardiomyopathy, the risk of all types of tachyarrhythmia, ICD therapy, or death was similar between Black patients and White patients. Both Black patients and White patients derived a significant and similar benefit from ICD implantation. CONCLUSIONS: Among patients with NICM with an ICD for primary prevention, Black patients compared with White patients had a high risk and burden of VTA, ATA, and ICD therapies with a lower survival rate. Nevertheless, the overall benefit of the ICD was maintained and was similar to that of White patients.

1 October 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MSMichael Shechter
Michael Shechter
RRRoy Rubinstein
Roy Rubinstein
IGIlan Goldenberg
Ilan Goldenberg
SMShlomi Matetzki
Shlomi Matetzki

6 February 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
MBMilica Bjelic
Milica Bjelic
IGIdo Goldenberg
Ido Goldenberg
AYArwa Younis
Arwa Younis
ACAnita Y. Chen
Anita Y. Chen
DHDavid T. Huang
David T. Huang
IGIlan Goldenberg
Ilan Goldenberg
Background: Sex‐specific risk management may improve outcomes in congenital long QT syndrome (LQTS). We recently developed a prediction score for cardiac events (CEs) and life‐threatening events (LTEs) in postadolescent women with LQTS. In the present study, we aimed to develop personalized risk estimates for the burden of CEs and LTEs in male adolescents with potassium channel‐mediated LQTS. Methods and Results: The prognostic model was derived from the LQTS Registry headquartered in Rochester, NY, comprising 611 LQT1 or LQT2 male adolescents from age 10 through 20 years, using the following variables: genotype/mutation location, QTc‐specific thresholds, history of syncope, and β‐blocker therapy. Anderson‐Gill modeling was performed for the end point of CE burden (total number of syncope, aborted cardiac arrest, and appropriate defibrillator shocks). The applicability of the CE prediction model was tested for the end point of the first LTE (excluding syncope and adding sudden cardiac death) using Cox modeling. A total of 270 CEs occurred during follow‐up. The genotype–phenotype risk prediction model identified low‐, intermediate‐, and high‐risk groups, comprising 74%, 14%, and 12% of the study population, respectively. Compared with the low‐risk group, high‐risk male subjects experienced a pronounced 5.2‐fold increased risk of recurrent CEs ( P <0.001), whereas intermediate‐risk patients had a 2.1‐fold ( P =0.004) increased risk . At age 20 years, the low‐, intermediate‐, and high‐risk adolescent male patients had on average 0.3, 0.6, and 1.4 CEs per person, respectively. Corresponding 10‐year adjusted probabilities for a first LTE were 2%, 6%, and 8%. Conclusions: Personalized genotype–phenotype risk estimates can be used to guide sex‐specific management in male adolescents with potassium channel‐mediated LQTS.